Inflammatory bowel disease: Management issues during pregnancy

Simone Ferrero, Nicola Ragni

Research output: Contribution to journalArticle

Abstract

Introduction: Inflammatory bowel disease often affects women during their reproductive years, causing management concerns for obstetricians caring for these patients during pregnancy. Treatment: Apart from methotrexate, most drugs used regularly to treat ulcerative colitis and Crohn's disease can safely be used by pregnant women. No causal relationship has been established between exposure to sulfasalazine or other 5-aminosalicylic acid drugs and the development of congenital malformations and these drugs may be used with relative safety during pregnancy and lactation. Current evidence indicates that maternal use of azathioprine and mercaptopurine is not associated with an increased risk of congenital malformations, though impaired foetal immunity, intrauterine growth retardation and prematurity are occasionally observed. Cyclosporin is not teratogenic, but may be associated with growth retardation and prematurity. Conclusions: Pregnancy should be avoided in women treated with methotrexate because of its known abortifacient effects and risk of causing typical malformations. There is no actual evidence of adverse effect in pregnant women receiving Infliximab but the amount of clinical information is small. The treatment with metronidazole or ciprofloxacin for short durations appear to be safe, but there is no data about the effects of increased length of treatment as required in Crohn's disease remains unknown. Control of disease activity before conception and during pregnancy is critical to optimise both maternal and foetal health. A multidisciplined approach involving both obstetrician and gastroenterologist and education about pregnancy are essential components of the treatment of any young women with IBD.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalArchives of Gynecology and Obstetrics
Volume270
Issue number2
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Disease Management
Inflammatory Bowel Diseases
Pregnancy
Methotrexate
Crohn Disease
Pregnant Women
Abortifacient Agents
Pharmaceutical Preparations
Mesalamine
6-Mercaptopurine
Sulfasalazine
Fetal Growth Retardation
Metronidazole
Azathioprine
Therapeutics
Ciprofloxacin
Ulcerative Colitis
Lactation
Cyclosporine
Immunity

Keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Pregnancy
  • Ulcerative colitis

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Inflammatory bowel disease : Management issues during pregnancy. / Ferrero, Simone; Ragni, Nicola.

In: Archives of Gynecology and Obstetrics, Vol. 270, No. 2, 09.2004, p. 79-85.

Research output: Contribution to journalArticle

@article{bfa1dbadbf414befa64a972e1c6c5199,
title = "Inflammatory bowel disease: Management issues during pregnancy",
abstract = "Introduction: Inflammatory bowel disease often affects women during their reproductive years, causing management concerns for obstetricians caring for these patients during pregnancy. Treatment: Apart from methotrexate, most drugs used regularly to treat ulcerative colitis and Crohn's disease can safely be used by pregnant women. No causal relationship has been established between exposure to sulfasalazine or other 5-aminosalicylic acid drugs and the development of congenital malformations and these drugs may be used with relative safety during pregnancy and lactation. Current evidence indicates that maternal use of azathioprine and mercaptopurine is not associated with an increased risk of congenital malformations, though impaired foetal immunity, intrauterine growth retardation and prematurity are occasionally observed. Cyclosporin is not teratogenic, but may be associated with growth retardation and prematurity. Conclusions: Pregnancy should be avoided in women treated with methotrexate because of its known abortifacient effects and risk of causing typical malformations. There is no actual evidence of adverse effect in pregnant women receiving Infliximab but the amount of clinical information is small. The treatment with metronidazole or ciprofloxacin for short durations appear to be safe, but there is no data about the effects of increased length of treatment as required in Crohn's disease remains unknown. Control of disease activity before conception and during pregnancy is critical to optimise both maternal and foetal health. A multidisciplined approach involving both obstetrician and gastroenterologist and education about pregnancy are essential components of the treatment of any young women with IBD.",
keywords = "Crohn's disease, Inflammatory bowel disease, Pregnancy, Ulcerative colitis",
author = "Simone Ferrero and Nicola Ragni",
year = "2004",
month = "9",
doi = "10.1007/s00404-003-0489-6",
language = "English",
volume = "270",
pages = "79--85",
journal = "Archives of Gynecology",
issn = "0170-9925",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Inflammatory bowel disease

T2 - Management issues during pregnancy

AU - Ferrero, Simone

AU - Ragni, Nicola

PY - 2004/9

Y1 - 2004/9

N2 - Introduction: Inflammatory bowel disease often affects women during their reproductive years, causing management concerns for obstetricians caring for these patients during pregnancy. Treatment: Apart from methotrexate, most drugs used regularly to treat ulcerative colitis and Crohn's disease can safely be used by pregnant women. No causal relationship has been established between exposure to sulfasalazine or other 5-aminosalicylic acid drugs and the development of congenital malformations and these drugs may be used with relative safety during pregnancy and lactation. Current evidence indicates that maternal use of azathioprine and mercaptopurine is not associated with an increased risk of congenital malformations, though impaired foetal immunity, intrauterine growth retardation and prematurity are occasionally observed. Cyclosporin is not teratogenic, but may be associated with growth retardation and prematurity. Conclusions: Pregnancy should be avoided in women treated with methotrexate because of its known abortifacient effects and risk of causing typical malformations. There is no actual evidence of adverse effect in pregnant women receiving Infliximab but the amount of clinical information is small. The treatment with metronidazole or ciprofloxacin for short durations appear to be safe, but there is no data about the effects of increased length of treatment as required in Crohn's disease remains unknown. Control of disease activity before conception and during pregnancy is critical to optimise both maternal and foetal health. A multidisciplined approach involving both obstetrician and gastroenterologist and education about pregnancy are essential components of the treatment of any young women with IBD.

AB - Introduction: Inflammatory bowel disease often affects women during their reproductive years, causing management concerns for obstetricians caring for these patients during pregnancy. Treatment: Apart from methotrexate, most drugs used regularly to treat ulcerative colitis and Crohn's disease can safely be used by pregnant women. No causal relationship has been established between exposure to sulfasalazine or other 5-aminosalicylic acid drugs and the development of congenital malformations and these drugs may be used with relative safety during pregnancy and lactation. Current evidence indicates that maternal use of azathioprine and mercaptopurine is not associated with an increased risk of congenital malformations, though impaired foetal immunity, intrauterine growth retardation and prematurity are occasionally observed. Cyclosporin is not teratogenic, but may be associated with growth retardation and prematurity. Conclusions: Pregnancy should be avoided in women treated with methotrexate because of its known abortifacient effects and risk of causing typical malformations. There is no actual evidence of adverse effect in pregnant women receiving Infliximab but the amount of clinical information is small. The treatment with metronidazole or ciprofloxacin for short durations appear to be safe, but there is no data about the effects of increased length of treatment as required in Crohn's disease remains unknown. Control of disease activity before conception and during pregnancy is critical to optimise both maternal and foetal health. A multidisciplined approach involving both obstetrician and gastroenterologist and education about pregnancy are essential components of the treatment of any young women with IBD.

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Pregnancy

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=4444245316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444245316&partnerID=8YFLogxK

U2 - 10.1007/s00404-003-0489-6

DO - 10.1007/s00404-003-0489-6

M3 - Article

C2 - 12721680

AN - SCOPUS:4444245316

VL - 270

SP - 79

EP - 85

JO - Archives of Gynecology

JF - Archives of Gynecology

SN - 0170-9925

IS - 2

ER -